Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received... von Qin, Shukui, Lin, Xiaoyan, Meng, Zhiqaing, Ren, Zhenggang, Bai, Yuxian, Gu, Shanzhi, Zheng, Li, Li, Qiu, Oh, Sun-Yong, Guo, Yabing, Kang, Yoong-Koo, Kao, Wei-Yu, Li, Wei, Yoon, Jung-Hwan, Zhang, Helong, Chen, Pei-Jer, Yang, Tsai-Sheng, Heo, Jeong, Zheng, Zhendong, Xie, Hui, Yu, Zhinuan

Volltext